Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis of the SURPASS Clinical Trials
Open Access
- 28 February 2025
- journal article
- research article
- Published by Springer Nature in Diabetes Therapy
- Vol. 16 (4) , 701-715
Abstract
Introduction Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist approved in the US for treating type 2 diabetes (T2D) and obesity, has demonstrated significant improvements in glycated hemoglobin A1c (HbA1c) and clinically meaningful weight loss in the SURPASS-1 to -5 clinical trials. This post hoc analysis examined the safety and efficacy results for tirzepatide in older participants with T2D who do not have obesity. Methods A post hoc analysis was conducted on a subgroup of participants aged ≥ 65 years with a body mass index (BMI) < 30 kg/m2 amongst the pooled SURPASS-1 through -5 clinical trial populations. Primary efficacy endpoints and safety were assessed for both this subgroup and overall pooled populations. Results Participants aged ≥ 65 years with BMI < 30 kg/m2 treated with tirzepatide experienced clinically meaningful HbA1c reduction (− 1.97 to − 2.10%) regardless of the assigned randomized maintenance dose. In contrast, a dose-proportional HbA1c decrease was observed in the overall population. Weight reduction in this subgroup was dose-proportional but numerically lower than in the overall population. Older participants without obesity were more likely to discontinue treatment due to adverse events (AEs), although the overall incidence of AEs was low in this subgroup. The incidence of hypoglycemia in this group was consistent with that of the overall cohort, regardless of concurrent insulin or sulfonylurea use. Conclusions Tirzepatide may be an effective treatment for older adults without obesity, and in this post hoc analysis, it was associated with clinically relevant HbA1c reduction and dose-proportional weight loss without increasing hypoglycemic risk.Keywords
Funding Information
- Eli Lilly and Company
This publication has 22 references indexed in Scilit:
- What is the Optimal Body Mass Index Range for Older Adults?Annals of Geriatric Medicine and Research, 2022
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 DiabetesJAMA, 2022
- Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UKBMJ Open Diabetes Research & Care, 2022
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trialThe Lancet, 2021
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 DiabetesNew England Journal of Medicine, 2021
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trialThe Lancet, 2021
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trialThe Lancet, 2021
- Evidence‐based diabetes care for older people with Type 2 diabetes: a critical reviewDiabetic Medicine, 2018
- BMI and all-cause mortality in older adults: a meta-analysisThe American Journal of Clinical Nutrition, 2014
- Body mass index and mortality in elderly men and women: the Tromsø and HUNT studiesJournal of Epidemiology and Community Health, 2011